NanoString Technologies (NanoString Technologies) Total Current Assets : $211.8 Mil (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is NanoString Technologies Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. NanoString Technologies's total current assets for the quarter that ended in Sep. 2023 was $211.8 Mil.

NanoString Technologies Total Current Assets Historical Data

The historical data trend for NanoString Technologies's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoString Technologies Total Current Assets Chart

NanoString Technologies Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

131.71

212.61

498.98

427.62

286.77

NanoString Technologies Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Current Assets	Get a 7-Day Free Trial															318.71	286.77	251.86	221.45	211.81

NanoString Technologies Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

NanoString Technologies's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	196.532	+	31.506	+	43.273	+	15.463
	=	286.8

NanoString Technologies's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	97.101	+	48.352	+	55.159	+	11.195
	=	211.8

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

NanoString Technologies (OTCPK:NSTGQ) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

NanoString Technologies's Liquidation Value for the quarter that ended in Sep. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	97.101	-	325.279	+	0.75 * 48.352	+	0.5 * 55.159
=	-164.3

NanoString Technologies Total Current Assets Related Terms

Thank you for viewing the detailed overview of NanoString Technologies's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

NanoString Technologies (NanoString Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoString Technologies Inc (OTCPK:NSTGQ) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

0F1:Germany

Address

530 Fairview Avenue North, Seattle, WA, USA, 98109

Website

https://www.nanostring.com

NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its core technology includes proprietary chemistries that enable the labeling and counting of single molecules. The firm uses its technology to develop tools for scientific and clinical research, primarily in the fields of genomics and proteomics. It offers two product platforms such as nCounter Analysis System or nCounter, and GeoMx Digital Spatial Profiler or DSP system both include instruments, related consumables, and software. NanoString Technologies generates revenue from the sale of products and related services and collaborations.

Executives

Jonathan Todd Garland	officer: Chief Commercial Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
K Thomas Bailey	officer: Chief Financial Officer	1618 STATION STREET, VANCOUVER A1 V6A 1B6
R Bradley Gray	director, officer: President and CEO	530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
William Young	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waite Charles P Jr	director, 10 percent owner	11023 NE 116TH STREET, KIRKLAND WA 98034
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Elisha W Finney	director	C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Teresa M. Foy	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Joseph M Beechem	officer: SVP, Research & Development	530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
John D. Gerace	officer: Chief Commercial Officer	C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Kirk Malloy	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
J. Chad Brown	officer: SVP, Sales & Marketing	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Janet George	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Dana E. Rollison	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109